SCH 58500

Drug Profile

SCH 58500

Alternative Names: p53 gene therapy - Schering-Plough; rAd/p53 - Schering-Plough; raDP-53 SCH 58500

Latest Information Update: 09 Jul 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co; Schering-Plough
  • Developer Merck & Co; Ore Pharmaceuticals
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Fallopian tube cancer; Head and neck cancer; Liver cancer; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer

Most Recent Events

  • 09 Jul 2014 Discontinued - Phase-I for Bladder cancer in USA (unspecified route)
  • 09 Jul 2014 Discontinued - Phase-I for Fallopian tube cancer in USA (Intraperitoneal)
  • 09 Jul 2014 Discontinued - Phase-I for Head and neck cancer in USA (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top